Purpose: We sought to determine whether race, gender and number of bladder cancer risk factors are significant predictors of hematuria evaluation. Materials and Methods: We used self-reported data from SCCS (Southern Community Cohort Study) linked to Medicare claims data. Evaluation of subjects diagnosed with incident hematuria was considered complete if imaging and cystoscopy were performed within 180 days of diagnosis. Exposures of interest were race, gender and risk factors for bladder cancer. Results: Of the 1,412 patients evaluation was complete in 261 (18%). On our adjusted analyses African American patients were less likely than Caucasian patients to undergo any aspect of evaluation, including urology referral (OR 0.72, 95% CI 0.56e0.93), cystoscopy (OR 0.67, 95% CI 0.50e0.89) and imaging (OR 0.75, 95% CI 0.59e0.95). Women were less likely than men to be referred to a urologist (OR 0.59, 95% CI 0.46e0.76). Also, although all patients with 2 or 3 risk factors had 31% higher odds of urology referral (OR 1.31, 95% CI 1.02e1.69), adjusted analyses indicated that this effect was only apparent among men. Conclusions: Only 18% of patients with an incident hematuria diagnosis underwent complete hematuria evaluation. Gender had a substantial effect on referral to urology when controlling for socioeconomic factors but otherwise it had an unclear role on the quality of evaluation. African American patients had markedly lower rates of thorough evaluation than Caucasian patients. Number of risk factors predicted referral to urology among men but it was otherwise a poor predictor of evaluation. There is opportunity for improvement by increasing the completion of hematuria evaluations, particularly in patients at high risk and those who are vulnerable.
ALTHOUGH bladder cancer has a higher prevalence in Caucasian than in African American individuals (22.8 vs 12.8/ 100,000 population) and a higher incidence in males than in females (36.6 vs 8.9/100,000 population), 5-year relative survival is worse in African American and female patients (82% in Caucasian males vs 76% in Caucasian females vs 69% in African American males vs 54% in African American females). 1 Multiple factors Accepted for publication June 9, 2017 . No direct or indirect commercial incentive associated with publishing this article.
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0022-5347/17/1985-1033/0 THE JOURNAL OF UROLOGY may contribute to this disparity, including tumor characteristics, and access to and quality of health care. 2, 3 Inadequate or delayed completion of hematuria evaluation may result in delayed diagnosis of bladder cancer and portend the observed inferior survival outcomes. Between 2.3% and 25.8% of hematuria workups result in the diagnosis of malignancy but population based studies indicate that only 9% to 36% of patients diagnosed with hematuria are adequately evaluated, including those considered at high risk. 4e9 We recently reported that women older than 65 years who present with hematuria more commonly have an incomplete or absent hematuria workup. 9 We have repeated this analysis using what is to our knowledge a novel data source, that is SCCS. This cohort was designed to study disparities in cancer risk and care. Our aim was to determine whether race and gender are significant predictors of hematuria evaluation even when controlling for patient specific socioeconomic status and risk factors. We also wanted to determine how risk factors for bladder cancer relate to the completeness of hematuria evaluation and whether they are weighted differently among race and gender groups.
METHODS

Database and Study Sample
This was an institutional review board approved study of medical procedures applied within 180 days of a hematuria diagnosis among participants in a prospectively accrued cohort, that is SCCS (http://www. southerncommunitystudy.org/). The cohort comprises about 85,000 generally low income individuals, of which two-thirds are African American and three-fifths are female, of whom all completed a baseline questionnaire highlighting socioeconomic and cancer risk factors such as smoking history and occupational exposures. 10 SCCS is linked to CMS data, allowing for studies of the association between baseline characteristics and downstream diagnoses, procedures and imaging. We used data collected on patients who were accrued between 2001 and 2009.
Study inclusion criteria included individuals 40 years old or older who were enrolled in SCCS and had continuous Medicare coverage for parts A and B without a health maintenance organization for 360 days before a diagnosis of incident hematuria as well as coverage for 180 days after the diagnosis. Subjects were included in analysis if a PCP diagnosed them with hematuria based on ICD-9 codes in the outpatient setting during the study period (supplementary Appendix and figure, http:// jurology.com/). For patients diagnosed with hematuria more than once the first diagnosis was determined to be the time of incident hematuria.
Study exclusion criteria included end stage renal disease as candidacy for Medicare coverage, any diagnosis of hematuria, genitourinary neoplasm or stone at any point before incident hematuria based on ICD-9 codes (360-day minimum), any genitourinary procedure within 360 days of incident hematuria based on ICD-9 codes or any genitourinary infection within 30 days of incident hematuria based on ICD-9 codes (supplementary Appendix and figure, http://jurology.com/).
Outcomes and End Points
The primary outcome of the study was receipt of a timely and complete hematuria evaluation. A hematuria evaluation was determined to be complete if cystoscopy and abdominopelvic imaging (ultrasound, computerized tomography, magnetic resonance imaging or retrograde pyelogram) were performed within 180 days of the incident hematuria event. Incomplete and absent evaluations were reported if 1 and both aspects of evaluation, respectively, were incomplete.
After the date of incident hematuria was established the determination of receipt of evaluation was based on ICD-9 or HCPCS (Healthcare Common Procedure Coding System) procedure codes (supplementary Appendix and figure, http://jurology.com/).
The secondary end points of the study were 1) referral to a urologist, which was a prerequisite for cystoscopy in most cases, and 2) diagnosis of a genitourinary malignancy. Diagnosis of a genitourinary malignancy (bladder cancer, kidney cancer or prostate cancer) was determined with the same ICD-9 codes used for exclusion criteria.
Exposures of Interest
We were interested in gender and race variation in evaluations for hematuria. We also studied the association between risk factors for bladder cancer and receipt of hematuria evaluation. Included factors were tobacco use, age greater than 50 years and occupational exposure (supplementary Appendix and figure, http://jurology.com/). Male gender and Caucasian race are known risk factors but they were not included in the tally of risk factors so that we could view gender and race differences in the completeness of the evaluation. Thus, patients were characterized at low riskd0 or 1 factors and high riskd2 or 3 factors for urological malignancy based on the 3 remaining risk factors being evaluated.
Although the magnitude of risk may have varied among factors (eg smoking carries more risk than occupational exposure), an inability to account for the varying magnitude of each risk factor (eg a 2 pack-year smoking history carries lower risk than a 50 pack-year history) resulted in our assignment of equal weight to each factor with regard to risk.
Covariates
Models were controlled for sociodemographic variables on the SCCS questionnaire, including household income, highest education level and marital status. Long-term current use of antiplatelets or anticoagulants was per ICD-9 codes (V58.61, V58.63, V58.66). We quantified patient comorbidity using the Klabunde adaptation of the Charlson comorbidity index from CMS data. 11 To quantify local health care resources we linked the SCCS-CMS data with the ARF (Area Resource File) to determine PCP density per 100,000 persons and urologist density per 100,000 persons in the county of patient residence.
Statistical Analysis
Standard descriptive statistics were used to describe the cohort. The Pearson chi-square test was applied to evaluate bivariate associations of race and gender with the primary and secondary end points.
We fit logistic regression models for each component of the evaluation (referral to urologist, receipt of imaging and procedure) and for complete evaluation (imaging and procedure). For the evaluation completeness model we used proportional odds logistic regression to model the log odds of receiving 1 category vs any category comprising the more thorough evaluation hierarchy of absent, incomplete or complete evaluation. In all of these models we allowed for interaction effects between the number of risk factors and race, and between the number of risk factors and gender. Age was modeled using a restricted cubic spline, which allows for a polynomial relationship between age and the log odds of the outcome. All analyses were performed using R, version 3.0.2 (https://www.r-project.org/).
RESULTS
A cohort of 1,412 patients met study inclusion criteria. Supplementary table 1 (http://jurology.com/) lists baseline cohort characteristics.
Imaging and cystoscopy were performed in 625 (44%) and 288 (20%) of the 1,412 patients, respectively. A total of 261 patients (18%) met the definition of having undergone a complete hematuria evaluation. Incomplete evaluations were observed in 391 patients (28%) while 760 (54%) evaluations were absent. PCPs referred 493 of the 1,412 patients (35%) to urologists after diagnosing incident hematuria. Of the 493 patients referred to urologists 287 (58%) underwent cystoscopy.
Effects
Race. On univariate analyses African American patients were less likely than Caucasian patients to undergo any part of the evaluation (urology referral 31% vs 40%, p <0.001; imaging 41% vs 47%, p ¼ 0.029; and cystoscopy 18% vs 25%, p ¼ 0.010, supplementary table 2, http://jurology.com/). These differences were also apparent after adjusting for risk factors and other covariates. The OR of comparing African American to Caucasian patients was 0.72 (95% CI 0.56e0.93) for urology referral, 0.67 (95% CI 0.50e0.89) for cystoscopy and 0.75 (95% CI 0.59e0.95) for imaging (table 1).
Gender. Overall women were less likely than men to be referred to a urologist (29% vs 45%, p <0.001, supplementary table 2, http://jurology.com/) or undergo cystoscopy (19% vs 23%, p ¼ 0.042). Adjusted analysis also showed large differences between men and women in urology referral (table 1) . Women were much less likely to be referred to a urologist than men (OR 0.59 95% CI 0.46e0.76). However, on adjusted analyses the extent of gender differences was less clear for imaging and cystoscopy.
Cancer Risk Factors. Patients with 2 or 3 risk factors were more likely to be referred to a urologist than those with 0 or 1 risk factor (38% vs 31%, p ¼ 0.004). There were no differences in the proportions who underwent imaging or cystoscopy between these risk groups. After adjusting for other factors averaged over race-gender strata patients with 2 or 3 risk factors had 31% higher odds of urology referral (OR 1.31, 95% CI 1.02e1.69, table 1). However, our adjusted analyses indicated that the effect was only apparent in men (see figure) .
Malignancy Diagnosis
Genitourinary malignancy was diagnosed in 31 of 1,412 cases (2.2%) (table 2). Malignancy was diagnosed in 8.8% of the patients who underwent a complete hematuria evaluation. Malignancy was only diagnosed in 1.3% and 0.4% of those who underwent an incomplete and absent evaluation, respectively. Of patients with 2 or more risk factors 3.0% were diagnosed with genitourinary malignancy compared to 1.4% of those with 0 or 1 risk factor.
DISCUSSION
In this study only 18% of patients with an incident diagnosis of hematuria underwent a complete hematuria evaluation while 54% underwent no imaging or procedure. On unadjusted analyses the likelihood of undergoing any part of the evaluation was lower in African American patients than Caucasian patients. These differences remained significant on adjusted analyses controlling for socioeconomic factors, availability of medical care and risk factors for bladder cancer. With regard to the effect of gender, women were less likely to be referred to a urologist or undergo cystoscopy on unadjusted analyses and they continued to be less likely referred to a urologist on adjusted analyses. Risk factors for bladder cancer were more likely to result in referral to a urologist but this effect was only apparent for men on adjusted analyses. The bladder cancer survival disparity seen in female and African American patients has been largely attributable to late presentation and higher stage malignancy at the time of diagnosis. 12, 13 In African American patients this discrepancy was hypothesized to be secondary to receipt of incomplete or delayed hematuria evaluations.
14 However, many factors could underlie the observed gender and race disparities in health outcomes, including economic and other barriers to health care (eg density of PCPs and urologists).
Social factors, particularly smoking and occupation, also vary between genders and among races. These differences are difficult to account for in large retrospective cohort studies. Using SCCS enabled us to derive a cohort with a majority of African American and female patients, and which contains granular information regarding socioeconomic factors and individual risk factors for bladder cancer. However, even when controlling for these patient specific and health care environment factors, effects of race and gender on the quality of hematuria evaluation persisted.
In addition to race and gender, we focused on the influence of risk factors for bladder cancer on the likelihood of hematuria evaluation. We found that a higher number of bladder cancer risk factors was associated with a higher rate of urologist referral in men. However, we failed to detect other statistically significant associations between risk factors for bladder cancer and the likelihood of undergoing a hematuria evaluation. This could mean that physicians do not account sufficiently for the individual risk of harboring malignancy when deciding whether to evaluate a patient with hematuria.
However, a lack of sufficient statistical power could also explain the absence of a statistical association. In this study 8.8% of those with a complete evaluation were found to have malignancy compared with 1.3% with an incomplete evaluation and 0.4% of those with no evaluation. If indeed hematuria evaluation decisions are not based on the risk of malignancy, a substantial number of occult malignancies could remain unidentified in patients who were not completely evaluated.
Our study has limitations inherent to its design. Our cohort was localized to the southeast United States and it consisted of a majority of African American and female individuals whose associated factors may not be generalizable to the national population, although they are representative of an important underserved and high risk population. Strict inclusion criteria also inhibit generalizability as many Estimated expected probability of evaluation outcomes by race-gender strata. Expected probabilities of referral to a urologist, receiving a component of hematuria evaluation (ie procedure or imaging) and both components (ie complete evaluation). Expected probabilities computed from multivariable models with baseline demographic, clinical, socioeconomic and environmental characteristics set to medians/modes. White, Caucasian. Black, African American.
real-world patients with hematuria have a history of urological malignancy, recent operations or infections.
Diagnoses and procedures were based on coding, which has inherent limitations. For example, the potential to incorrectly code hematuria based on a dipstick test may certainly explain the low referral numbers and the meager 18% incidence of complete hematuria. These misdiagnoses of hematuria may also result in a urologist screening out patients who do not truly have hematuria. This may in part explain why only 58% of the patients referred to a urologist underwent cystoscopy. Even in the event that hematuria was properly coded, we also could not easily quantify the severity of hematuria (ie gross vs microscopic or number of red blood cells per high power field).
Despite these limitations this study provides a novel perspective into the discrepancy of hematuria evaluation in groups that are often underrepresented in bladder cancer outcomes studies, that is female and African American patients. The baseline SCCS questionnaire allows for the determination of social risk factors for urological malignancy as well as socioeconomic factors. The linkage to Medicare allows for the determination of diagnosis and receipt of care, which are details that are also often lacking in large retrospective outcomes studies. Finally, the linkage to area health resources enabled us to control to an extent for availability of health care services.
Although this study helps highlight discrepancies in hematuria evaluation among different race and gender groups, it also accentuates overall poor adherence to guidelines for adults with microscopic hematuria in that only 18% of patients in our study received a complete evaluation based on AUA (American Urological Association) guidelines. 15 Urinary malignancies discovered during microscopic hematuria evaluation are relatively uncommon. They are reported at a rate of between 0.4% and 13% in patients evaluated by a urologist with more recent studies supporting a rate of 5% or less. In light of this some groups have made efforts to target evaluation of those at higher risk for urological malignancy and avoid unnecessary evaluation in patients at very low risk. In a prospective cohort study Loo et al created a Hematuria Risk Index using age greater than 50 years, history of gross hematuria, degree of current microhematuria, smoking history and male gender as factors to determine which patients with microscopic hematuria should undergo a complete evaluation. 16 Although the results lack external validation, the investigators noted the potential to risk stratify patients into groups and more efficiently identify most malignancies while performing far fewer evaluations.
While this stratification may have merit, one must be mindful that urinary malignancy is not surprisingly discovered by higher rates of microscopic hematuria in patients referred to a urologist compared to microscopic hematuria in the general population. 7, 20 Given that only 35% of patients with hematuria in our study were referred to a urologist, it is reasonable to maintain a broad net for urology referral of microscopic hematuria and reserve risk stratification for urological consultation.
CONCLUSIONS
Using what is to our knowledge a novel cohort we report that race and gender differences in hematuria evaluation persisted even when accounting for socioeconomic and health care environmental factors. Furthermore, we did not find a statistically significant association between the risk factors for malignancy in an individual and receipt of a complete hematuria evaluation in any race or gender group. Overall only 18% of patients with incident hematuria underwent a complete evaluation. The current approach to hematuria evaluation leaves a large proportion of socially vulnerable patients and those at high risk unevaluated, which could have deleterious consequences in those harboring occult malignancy. 
Hematuria evaluation was deemed complete if cystoscopy and abdominopelvic imaging (ultrasound, computerized tomography, magnetic resonance imaging or retrograde pyelogram) were performed within 180 days of incident hematuria event, incomplete if only cystoscopy or imaging was completed within 180 days and absent if neither imaging nor procedure was completed.
